CMR Imaging With Rapid Visual T1 Assessment Predicts Mortality in Patients Suspected of Cardiac Amyloidosis

被引:115
作者
White, James A. [1 ,2 ,3 ]
Kim, Han W. [5 ]
Shah, Dipan
Fine, Nowell [1 ]
Kim, Ki-Young
Wendell, David C. [4 ]
Al-Jaroudi, Wael [4 ]
Parker, Michele [4 ,5 ]
Patel, Manesh [4 ,5 ]
Gwadry-Sridhar, Femida
Judd, Robert M. [5 ,6 ]
Kim, Raymond J. [4 ,5 ,6 ]
机构
[1] Univ Western Ontario, Div Cardiol, London Hlth Sci Ctr, London, ON, Canada
[2] Univ Western Ontario, Robarts Res Inst, London, ON, Canada
[3] Univ Western Ontario, Lawson Hlth Res Inst, London, ON, Canada
[4] Duke Univ, Med Ctr, Duke Cardiovasc Magnet Resonance Ctr, Durham, NC USA
[5] Duke Univ, Med Ctr, Div Cardiol, Durham, NC USA
[6] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA
基金
美国国家卫生研究院; 美国医疗保健研究与质量局;
关键词
amyloid; magnetic resonance imaging; delayed enhancement; CARDIOVASCULAR MAGNETIC-RESONANCE; ENDOMYOCARDIAL BIOPSY; ENHANCEMENT; MANAGEMENT; DIAGNOSIS; SURVIVAL;
D O I
10.1016/j.jcmg.2013.09.019
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
OBJECTIVES This study tested the diagnostic and prognostic utility of a rapid, visual T1 assessment method for identification of cardiac amyloidosis (CA) in a "real-life" referral population undergoing cardiac magnetic resonance for suspected CA. BACKGROUND In patients with confirmed CA, delayed-enhancement cardiac magnetic resonance (DE-CMR) frequently shows a diffuse, global hyperenhancement (HE) pattern. However, imaging is often technically challenging, and the prognostic significance of diffuse HE is unclear. METHODS Ninety consecutive patients referred for suspected CA and 64 hypertensive patients with left ventricular hypertrophy (LVH) were prospectively enrolled and underwent a modified DE-CMR protocol. After gadolinium administration a method for rapid, visual T1 assessment was used to identify the presence of diffuse HE during the scan, allowing immediate optimization of settings for the conventional DE-CMR that followed. The primary endpoint was all-cause mortality. RESULTS Among patients with suspected CA, 66% (59 of 90) demonstrated HE, with 81% (48 of 59) of these meeting pre-specified visual T1 assessment criteria for diffuse HE. Among hypertensive LVH patients, 6% (4 of 64) had HE, with none having diffuse HE. During 29 months of follow-up (interquartile range: 12 to 44 months), there were 50 (56%) deaths in patients with suspected CA and 4 (6%) in patients with hypertensive LVH. Multivariable analysis demonstrated that the presence of diffuse HE was the most important predictor of death in the group with suspected CA (hazard ratio: 5.5, 95% confidence interval: 2.7 to 11.0; p < 0.0001) and in the population as a whole (hazard ratio: 6.0, 95% confidence interval 3.0 to 12.1; p < 0.0001). Among 25 patients with myocardial histology obtained during follow-up, the sensitivity, specificity, and accuracy of diffuse HE in the diagnosis of CA were 93%, 70%, and 84%, respectively. CONCLUSIONS Among patients suspected of CA, the presence of diffuse HE by visual T1 assessment accurately identifies patients with histologically-proven CA and is a strong predictor of mortality. (J Am Coll Cardiol Img 2014;7:143-56) (C) 2014 by the American College of Cardiology Foundation
引用
收藏
页码:143 / 156
页数:14
相关论文
共 30 条
[1]
Delayed Hyper-Enhancement Magnetic Resonance Imaging Provides Incremental Diagnostic and Prognostic Utility in Suspected Cardiac Amyloidosis [J].
Austin, Bethany A. ;
Tang, W. H. Wilson ;
Rodriguez, E. Rene ;
Tan, Carmela ;
Flamm, Scott D. ;
Taylor, David O. ;
Starling, Randall C. ;
Desai, Milind Y. .
JACC-CARDIOVASCULAR IMAGING, 2009, 2 (12) :1369-1377
[2]
Independent Predictors of Survival in Primary Systemic (AL) Amyloidosis, Including Cardiac Biomarkers and Left Ventricular Strain Imaging: An Observational Cohort Study [J].
Bellavia, Diego ;
Pellikka, Patricia A. ;
Al-Zahrani, Ghormallah B. ;
Abraham, Theodore P. ;
Dispenzieri, Angela ;
Miyazaki, Chinami ;
Lacy, Martha ;
Scott, Christopher G. ;
Oh, Jae K. ;
Miller, Fletcher A., Jr. .
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2010, 23 (06) :643-652
[3]
Chung YC, 2002, P INT SOC MAGN RESON, V10, P219
[4]
The role of endomyocardial biopsy in the management of cardiovascular disease - A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology [J].
Cooper, Leslie T. ;
Baughman, Kenneth L. ;
Feldman, Arthur M. ;
Frustaci, Andrea ;
Jessup, Mariell ;
Kuhl, Uwe ;
Levine, Glenn N. ;
Narula, Jagat ;
Starling, Randall C. ;
Towbin, Jeffrey ;
Virmani, Renu .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (19) :1914-1931
[5]
Diagnosis and management of the cardiac amyloidoses [J].
Falk, RH .
CIRCULATION, 2005, 112 (13) :2047-2060
[6]
Single-shot inversion recovery trueFISP for assessment of myocardial infarction [J].
Huber, A ;
Schoenberg, SO ;
Spannag, B ;
Rieber, J ;
Erhard, I ;
Klauss, V ;
Reiser, MF .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2006, 186 (03) :627-633
[7]
Extracellular volume fraction mapping in the myocardium, part 2: initial clinical experience [J].
Kellman, Peter ;
Wilson, Joel R. ;
Xue, Hui ;
Bandettini, W. Patricia ;
Shanbhag, Sujata M. ;
Druey, Kirk M. ;
Ugander, Martin ;
Arai, Andrew E. .
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE, 2012, 14
[8]
Amyloid in the cardiovascular system:: a review [J].
Kholová, I ;
Niessen, HWM .
JOURNAL OF CLINICAL PATHOLOGY, 2005, 58 (02) :125-133
[9]
The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. [J].
Kim, RJ ;
Wu, E ;
Rafael, A ;
Chen, EL ;
Parker, MA ;
Simonetti, O ;
Klocke, FJ ;
Bonow, RO ;
Judd, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (20) :1445-1453
[10]
How we perform delayed enhancement imaging [J].
Kim, RJ ;
Shah, DJ ;
Judd, RM .
JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE, 2003, 5 (03) :505-514